Results 241 to 250 of about 2,176,289 (311)

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

Molecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel, Izabela Kubiak, Lena Rutkowska, Żaneta Kasprzyk, Łukasz Kępczyński, Michał Bednarek, Dariusz Sobieraj, Jacek Wilkosz, Piotr Kania, Adam Jędrzejczyk, Bogdan Kałużewski, Agnieszka Gach, Tadeusz Kałużewski   +12 more
wiley   +1 more source

A phantom decoy shifts wild forager decisions in a natural environment. [PDF]

Behav Ecol
Jarvis GR, Banks PB, Latty T, Possell M, Orlando CG, McArthur C.   +5 more
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Lived experiences and decision making among patients and caregivers choosing conservative kidney management: A qualitative study. [PDF]

Palliat Care Soc Pract
Loh SP, Tan AJQ, Lau WL, Chiang SY, Yeoh LY, Teh SP, Long PWY.   +6 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

The Agentic AI Framework (AAIF): a policy-enforced architecture for accountable and high-performance intrusion detection. [PDF]

Front Artif Intell
Adabara I, Sadiq BO, Shuaibu AN, Danjuma YI, Maninti V, Joe M.   +5 more
europepmc   +1 more source

Quantitative Medicine to Support Drug Development and Regulatory Decisions: A UK Regulatory Approach Informed by ICH M15. [PDF]

Clin Transl Sci
Kerwash E, Butler AS, Malamatari M, Cole S.   +3 more
europepmc   +1 more source

The imperative to embed ethics in health research priority-setting. [PDF]

Bull World Health Organ
Millum J, Aguilera B, Bhaumik S, Galvagni E, Littler K, Munung NS, Pierson L, Pratt B.   +7 more
europepmc   +1 more source

Social decision-making of Japanese male spouses following their wives' breast cancer diagnosis: A quantitative content analysis. [PDF]

Support Care Cancer
Yamauchi K, Nakashima M, Nakao M.
europepmc   +1 more source

Large Language Models as Decision-support Tools for Adjuvant Therapy Planning in Early-stage Hormone Receptor-positive Breast Cancer. [PDF]

Cancer Diagn Progn
Karabuğa B, Büyükkör M, Karabuğa EK, Aydemir E, Kaya OB, Yilmaz ME, Kaptan E, Ateş Ö, Yildiz F.   +8 more
europepmc   +1 more source